Synapse - Robert Motzer

Results (1248)

Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma

Journal Article

Motzer, R. J.; Haas, N. B.; Donskov, F.; Gross-Goupil, M.; Varlamov, S.; Kopyltsov, E.; Lee, J. L.; Melichar, B.; Rini, B. I.; Choueiri, T. K.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Perioperative management of localized kidney cancer: Watching and waiting

Journal Article

Voss, M. H.; Motzer, R. J.
JAMA Oncology (2017)

Fulltext@MSK | Save

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Journal Article

Voss, M. H.; Hussain, A.; Vogelzang, N.; Lee, J. L.; Keam, B.; Rha, S. Y.; Vaishampayan, U.; Harris, W. B.; Richey, S.; Randall, J. M.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Overall survival (OS) in METEOR, a randomised phase III trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma (RCC)

Meeting Abstract

Mainwaring, P.; Powles, T.; Escudier, B. J.; Tannir, N. M.; Rini, B. I.; Hammers, H. J.; Donskov, F.; Roth, B. J.; Peltola, K.; Lee, J. L.; more...
Asia-Pacific Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts)

Meeting Abstract

Grünwald, V.; McDermott, D. F.; Atkins, M.; Motzer, R.; Rini, B.; Escudier, B.; Fong, L.; Joseph, R.; Pal, S. K.; Sznol, M. M. D.; more...
Oncology Research and Treatment (2017)

Fulltext@MSK | Save

Potential impact of avelumab + axitinib (A + Ax) on tumor size (TS) compared with historical data of sunitinib (S) as evaluated by a modeling and simulation (MS) approach

Meeting Abstract

Zheng, J.; Chang, A.; Larkin, J.; Motzer, R. J.; Amantea, M.; Bello, C.; Pavlov, D.; Geraldes, M.; Martignoni, M.; Di Pietro, A.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial

Meeting Abstract

Staehler, M.; Motzer, R. J.; George, D. J.; Pandha, H. S.; Donskov, F.; Escudier, B.; Kliment, J.; Pantuck, A. J.; Patel, A.; Deannuntis, L.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Powles, T.; McDermott, D. F.; Rini, B.; Motzer, R. J.; Atkins, M. B.; Fong, L.; Joseph, R. W.; Pal, S. K.; Ravaud, A.; Bracarda, S.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)

Meeting Abstract

Powles, T.; Motzer, R. J.; George, D. J.; Jonasch, E.; Pal, S.; Tannir, N. M.; Signoretti, S.; Mai, T. H.; Scheffold, C.; Wang, E.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma

Meeting Abstract

Lee, C. H.; Makker, V.; Rasco, D.; Taylor, M.; Dutcus, C.; Shumaker, R.; Schmidt, E. V.; Stepan, D.; Li, D.; Motzer, R. J.
Annals of Oncology (2017)

Fulltext@MSK | Save